ArticleBMC health services research2017

Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.

Daniel Wirth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.